Orchid Pharma approves amalgamation of Dhanuka Pharma with itself

Issues 10,000 equity shares of OPL for Rs 10 each at par to the shareholders of DPPL

Orchid Pharma approves amalgamation of Dhanuka Pharma with itself
BS Reporter Chennai
2 min read Last Updated : Apr 03 2020 | 8:57 PM IST
The monitoring committee of Orchid Pharma Ltd (OPL) has approved the amalgamation of Dhanuka Pharmaceuticals Pvt Ltd (DPPL) into the company, and has issued 10,000 equity shares of OPL with a face value of Rs 10 each to the shareholders of DPPL, towards this end. The amalgamation scheme is is part of Dhanuka Laboratories (DLL)'s resolution plan to revive OPL.

As per the plan, OPL has issued 39.99 million equity shares of Rs 10 each to Dhanuka Laboratories Limited (DLL). The committee also issued 143,000 optionally convertible debentures of Rs 1,00,000 each amounting to Rs 143 crore to DLL. Four members from Dhanuka have also been co-opted on OPL's board.  

As part of the resolution plan, DLL infused Rs 370 crore and another Rs 40 crore into OPL. A third tranche of Rs 200 crore was made well within a period of a year from the implementation of resolution plan, as per its terms.

Lenders have been able to recover Rs 1,106.50 crore out of the total admitted debt of Rs 3,526.74 crore, apart from getting a one per cent shareholding. Some 4,08,164 equity shares have been issued to 22 secured financial creditors based on their exposure to the company.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Orchid Pharma

Next Story